Alex ZissonManaging Director at H.I.G. Capital
Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. Capital as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics, Leiter’s, and Neurana Pharma. Prior to H.I.G., Alex was spent 13 years making similar investments at Thomas, McNerney & Partners. Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist. During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.